Fig 1.
a. PD-1-positive expression in mononuclear cells in tumor tissue (x 400). b. PD-L1-positive expression in tumor cells (x 200). c. Foxp3-positive expression in mononuclear cells in tumor tissue (x 400). d. TGF-β-positive expression in tumor cells (x 200). e. IDO-positive expression in tumor cells (x 200).
Table 1.
Patient and tumor characteristics.
Table 2.
Univariate analysis of prognostic factors for colorectal cancer (CRC).
Table 3.
Multivariate analysis of prognostic factors in colorectal cancer (CRC).
Fig 2.
The overall survival rates in the right sided CRC.
Kaplan–Meier analysis of 5-year overall survival for IDO expression. The OS rates was significantly poorer in the IDO-positive group (n = 9) than in the IDO-negative group (n = 18) (5-year OS rate, 75.0% vs. 100%, respectively).
Table 4.
Univariate analysis of prognostic factors for right-sided colorectal cancer (CRC).
Fig 3.
The overall survival rates in the left sided CRC.
a. Kaplan–Meier analysis of 5-year overall survival for PD-1expression. The OS rates was significantly poorer in the PD-1-positive group (n = 21) than in the PD-1-negative group (n = 54) (5-year OS rate, 80.7% vs. 98.1%, respectively). b. Kaplan–Meier analysis of 5-year overall survival for PD-L1 expression. The OS rates was significantly poorer in the PD-L1-positive group (n = 15) than in the PD-L1-negative group (n = 60) (5-year OS rate, 75.4% vs. 91.4%, respectively). c. Kaplan–Meier analysis of 5-year overall survival for Foxp3 expression. The OS rates was significantly poorer in the Foxp3-positive group (n = 43) than in the Foxp3-negative group (n = 32) (5-year OS rate, 82.7% vs. 96.5%, respectively).
Table 5.
Univariate analysis of prognostic factors for left-sided colorectal cancer (CRC).